



Protalix BioTherapeutics to Present at Three International Healthcare Conferences and ImmunoGen, Inc. Announces Presentations at Upcoming 2008 American Society of Clinical Oncology Annual Meeting

May 23, 2008

--(www.USEquityNews.com)-- 05/23/2008 - Healthcare industry alert provided by U.S. Equity News. Protalix BioTherapeutics, Inc. (AMEX: PLX), recently announced that Dr. David Aviezer, the Company's President and Chief Executive Officer, will be presenting at the 7th National Life Science Week, Biomed Conference and at the 2008 Bio International Convention. Additionally, the Company will be giving a presentation on its ongoing clinical development program for the treatment of Gaucher Disease at the 8th European Working Group on Gaucher Disease Meeting. Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system.

Shares of biopharmaceutical company GTx Inc. (NASDAQ: GTXI) fell Friday after the company said a late-stage trial of its prostate cancer drug candidate needs to continue, precluding a early filing with the Food & Drug Administration. Shares dropped \$1.31, or 8 percent, to \$14.93 in morning trading. An independent group determined that the Acapodene trial should continue based on an interim analysis of data.

ImmunoGen, Inc. (NASDAQ: IMGN) recently announced that new clinical data will be reported at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting with three targeted anticancer compounds in development by the Company and its collaborators. The ASCO annual meeting will be held May 30 to June 3, 2008 in Chicago, IL. "We're looking forward to an exciting ASCO meeting this year and to the presentation of new findings with both our IMGN242 anticancer agent and two compounds in development through our collaborations," commented Mitchel Sayare, Chairman and CEO. "We're pleased with the progress being made as we - and our partners - work to achieve significant new treatments for cancer."

TapImmune Inc. (OTCBB: TPIM) announces completion of initial testing on our bench made vaccine at AppTech. The company now has the necessary data to proceed with clinical grade vaccine stock production. Going forward, our work and development program includes phased manufacturing and production for both infectious disease adjuvant and cancer therapeutic vaccine candidates. These will culminate in toxicology studies and will coincide with pre-IND meeting preparation with the FDA and clinical protocols for our proposed phase 1 human studies. This milestone is predicated on the back of a year where we have seen the completion of the UBC assignment agreement finally effecting our acquisition of the core technologies we developed under the world-wide license agreement.

About U.S. Equity News

U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.

U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equitysolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.

Source: Financial News USA (May 23, 2008 - 12:59 PM EDT)

News by QuoteMedia
www.quotemedia.com